Therapeutics News and Research

RSS

ShangPharma achieves initial milestones for two oncology projects

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it has achieved the initial milestones for two multi-staged projects in its biologics division, which portends strong growth for this segment in 2011.

11 Aug 2011

InVivo Therapeutics reports net loss of $1,370,000 for second quarter 2011

InVivo Therapeutics Holdings Corp., a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today reported financial results for the three and six months ended June 30, 2011 and provided a business update.

11 Aug 2011

New research uncovers role of p38alpha in mood disorders, addiction

Stressful experiences increase addictive drug consumption and can precipitate bouts of anxiety or depression in vulnerable people. Although the mechanisms linking stress and human behaviors are not well understood, animal models of some aspects of these behaviors have been developed and have been used to define some of the molecular events that may be responsible for stress vulnerability in people.

11 Aug 2011

Guided Therapeutics initiates human trial for light-based Barrett's Esophagus detection technology

Guided Therapeutics, Inc., developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it has begun human testing of its light-based detection technology for Barrett's Esophagus, a precursor for esophageal cancer. The technology is being jointly developed with Konica Minolta Opto of Japan.

11 Aug 2011

FDA approves Gilead's Complera for treatment of HIV-1 infection

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Complera, a complete single-tablet regimen for the treatment of HIV-1 infection in treatment-naïve adults.

11 Aug 2011

BELLUS Health second quarter revenues increase to $719,000

BELLUS Health Inc. reported today its financial results for the second quarter ended June 30, 2011.

10 Aug 2011

Protox reports net loss of $3.2 million for second quarter 2011

Protox Therapeutics Inc., a developer of innovative products for the treatment of urological diseases, today announced financial results and achievements for the quarter ended June 30, 2011.

10 Aug 2011

Acorda Therapeutics receives U.S. patent allowance for aminopyridine compositions

Acorda Therapeutics, Inc. today announced that the United States Patent and Trademark Office (USPTO) has allowed U.S. Patent Application No. 11/102,559 entitled "Method of Using Sustained Release Aminopyridine Compositions."

10 Aug 2011

BIDMC researchers receive PCF Challenge Awards for novel prostate cancer study

Beth Israel Deaconess Medical Center (BIDMC) researchers Martin Sanda, MD, and Steven Balk MD, PhD, have been awarded Challenge Awards of $1 million each from the Prostate Cancer Foundation (PCF) to lead two cross-disciplinary teams of investigators in their pursuit of new treatments for patients with advanced prostate cancer.

10 Aug 2011

Enobia raises US$40M through private placement

Enobia Pharma Inc., a clinical stage biotech company focused on developing novel therapeutics for serious bone disorders, today announced that it has raised US$40 million through the private placement of approximately 13,724,000 shares of its common stock to new pharmaceutical and financial investors.

10 Aug 2011

Akela announces new corporate focus on PharmaForm

Akela Pharma, Inc. today announced a new strategic focus on its profitable pharmaceutical contract manufacturing business, PharmaForm, LLC.

9 Aug 2011

InVivo announces Platinum sponsorship to W2W spinal cord injury symposium

InVivo Therapeutics today announced the Company's Platinum level sponsorship of the 6th annual Working 2 Walk Science and Advocacy Symposium, which will take place October 16-18, 2011 in Rockville, Maryland.

9 Aug 2011

Nottingham researchers to develop new early warning system for Alzheimer's

Researchers at The University of Nottingham have been awarded £670,000 to develop a new early warning system for Alzheimer's disease.

9 Aug 2011

New preclinical approach can guide more efficient drug development for brain-related conditions

The development of drugs for brain-related conditions is not an efficient process; only 8% of candidate drugs that enter clinical trials gain FDA approval. A key reason for this low success rate is a lack of preclinical tests that accurately predict drug efficacy and detect unwanted side effects.

9 Aug 2011

EPO issues European patent for Rexahn's neurotherapeutic compositions

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office (EPO) has granted European patent No. EP1212055 entitled "Neurotherapeutic compositions comprising a beta-lactam compound."

9 Aug 2011

Kaan Medikal to distribute Saladax's My5-FU diagnostic test in Turkey

Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that Kaan Medikal will serve as the exclusive distributor of Saladax's My5-FU diagnostic test throughout the Turkish market.

8 Aug 2011

Unigene second quarter revenue decreases to $2.5 million

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced second quarter financial results for the period ended June 30, 2011. The Company highlighted significant progress achieved in the second quarter with the continued execution of its turnaround strategy.

8 Aug 2011

Researchers team up to combat age-related macular degeneration

A professor at the University of California, Riverside Bourns College of Engineering has received a $100,000 grant to develop a new technique to fight a disease that gradually destroys vision.

8 Aug 2011

Idera second quarter net loss increases to $6.3 million

Idera Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-Like receptors (TLRs).

5 Aug 2011

Osiris second quarter revenues increase to $10.4 million

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory and cardiovascular disease areas and wound healing, announced today its results for the second quarter ended June 30, 2011.

5 Aug 2011